Former OpenAI Science Lead Kevin Weil Launches Warp Sciences With $215M to Automate Drug Discovery

4 Sources

Share

Kevin Weil, former OpenAI science lead, launched Warp Sciences with $215 million in funding at an $865 million valuation. The startup uses AI and robotics to automate wet labs for drug development, aiming to reshore chemistry work from China and address geopolitical supply-chain risks while accelerating molecule optimization through robotic automation.

Former OpenAI Science Lead Kevin Weil Launches Warp Sciences

Kevin Weil, who led OpenAI's science initiatives until his departure in April, has emerged from stealth with Warp Sciences, an AI drug discovery startup that secured $215 million in funding at an $865 million valuation

1

2

. Lightspeed Venture Partners led the round, with participation from IVP, Premji Invest, Lux Capital, Mayfield, Conviction, Menlo Ventures, and 01 Advisors

3

. Notable angel investors include OpenAI CFO Sarah Friar, Coinbase CEO Brian Armstrong, LinkedIn co-founder Reid Hoffman, Databricks co-founder Ion Stoica, and Figma CEO Dylan Field

2

3

.

Source: The Next Web

Source: The Next Web

Building a Chemistry Contract Research Organization With AI and Robotics

Warp Sciences positions itself as a chemistry contract research organization focused on automating wet labs to accelerate drug development

4

. The startup's initial service centers on lead optimization through analog synthesis, producing hundreds or thousands of molecular variations of promising compounds so researchers can identify the best drug candidates

3

4

. This molecule optimization work has traditionally been outsourced to Chinese contractors like WuXi AppTec because they offer faster turnaround times and lower costs

2

.

The company's approach combines human expertise with robotic automation. Warp's chemists wear cameras and pressure-sensing gloves during experiments, generating training data for AI models that will increasingly automate laboratory tasks

1

2

. The team of approximately 20 has already acquired robotic arms and AI chips to build out their automated infrastructure

2

.

Source: SiliconANGLE

Source: SiliconANGLE

Addressing Geopolitical Supply-Chain Risks and Intellectual Property Protection

Warp Sciences aims to reshore chemistry work to the United States, directly addressing geopolitical supply-chain risks that have intensified amid US-China tensions

1

. In June, the Pentagon added WuXi AppTec to its list of companies allegedly linked to China's military, though a judge blocked the designation in August

2

. The BIOSECURE Act, signed into law by President Donald Trump in December, now restricts federal contracts and grants involving designated biotechnology companies of concern

4

. A 2024 Biotechnology Innovation Organization survey found that 74% of 124 biotech companies maintained contracts with Chinese firms for preclinical and clinical services

4

.

Co-founder and Chief Scientific Officer Solomon Reisberg, who previously led medicinal chemistry at Terremoto Biosciences, emphasized intellectual property protection as a core concern. "I've worked with overseas chemistry partners that delivered speed and value, but I still worried about protecting the intellectual property behind our programs," Reisberg said

3

. Warp aims to match the quality and speed of overseas partners while eliminating the price premium typically charged by US boutique contract research organizations

3

4

.

Creating Real-World Data to Advance AI-Powered Drug Research Labs

Kevin Weil explained that AI has yet to transform physical sciences the way it has revolutionized software engineering and mathematics. "It's still an area where frontier AI models are not yet changing the world in the way models are changing the world in software engineering and math," Weil said. "That's because the field is so much more experimentally driven. The models need to see that data"

2

. Warp's strategy centers on generating real-world experimental data at scale to train more capable AI systems for compound synthesis and drug development

3

.

Co-founder and Chief Technology Officer Manohar Paluri, former vice president at Meta Superintelligence Labs, emphasized creating a feedback loop between molecular design, laboratory testing, and subsequent research. "Every experiment should make the next one smarter," Paluri said

3

. By connecting experiment design, execution, and analysis through AI models trained on laboratory data, Warp aims to build systems that can better determine what molecules to make and how to synthesize them

3

.

Infrastructure Play Rather Than Drug Pipeline Development

Warp Sciences will not develop its own drug candidates. Co-founder and Chief Operating Officer DJ Patil, who served as the White House's first chief data scientist and was a founding executive at Devoted Health, clarified the company's positioning: "We're not developing drugs of our own. We're building the infrastructure for the people who do"

3

4

. Customers retain complete control over their drug discovery programs and decide which molecules to pursue

3

. This contractor model allows pharmaceutical and biotechnology companies to maintain ownership of their research while benefiting from Warp's automated capabilities and US-based operations

4

.

Growing Investment in AI for Drug Discovery

Warp Sciences joins a wave of AI drug discovery startups attracting significant capital. OpenAI-backed Chai Discovery raised $400 million in July

2

. This week, OpenAI acquired Orchestra Bio, which helps drugmakers run drug development with AI agents

2

. OpenAI researcher Miles Wang was reported to be raising approximately $200 million for his own drug startup, with Lightspeed Venture Partners in talks to lead that round as well

2

. Earlier this week, Bob McGrew, another former OpenAI leader, raised $232 million for Arda, which builds AI systems to set up factory lines

2

. The convergence of AI capabilities with physical sciences infrastructure suggests investors anticipate substantial returns from automating laboratory work and accelerating the path from molecular discovery to clinical candidates.

© 2026 TheOutpost.AI All rights reserved